Description – Dr. Ajai Chari and Dr. Rahul Banerjee conclude the discussion by exploring future opportunities to further improve outcomes for patients with relapsed/refractory multiple myeloma (RRMM). The faculty discuss the continued evolution of T-cell–redirecting therapies, including efforts to move bispecific antibodies into earlier lines of treatment and strategies aimed at achieving deeper, more durable responses. Dr. Banerjee highlights emerging approaches such as trispecific antibodies, including agents designed to simultaneously target multiple myeloma antigens, as well as the potential role of cereblon E3 ligase modulators (CELMoDs) in enhancing T-cell function and overcoming treatment resistance. Dr. Chari and Dr. Banerjee also examine ongoing efforts to optimize treatment duration, improve accessibility of novel therapies in community practice settings, and reduce treatment-related toxicities to broaden patient access. The conversation emphasizes the importance of preserving T-cell fitness, developing innovative combination strategies, and identifying additional therapeutic targets as the field continues to advance. The segment concludes with key takeaways from the MonumenTAL-3 data and a discussion of how GPRC5D-directed therapies may contribute to the future management of RRMM.
